Combining therapies for the treatment of migraine: Is there a role?

Expert Review of Neurotherapeutics

Volumn 5, Issue 2, 2005, Pages 145-147

  Krymchantowski, Abouch Valenty ^a,b  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Instituto de Neurologia Deolindo Couto   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT DERIVATIVE; METOCLOPRAMIDE; NADOLOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROCHLORPERAZINE; PROPRANOLOL; RIZATRIPTAN; ROFECOXIB; SEROTONIN 1B AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

DISEASE SEVERITY; EDITORIAL; HEADACHE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; SIDE EFFECT; WEIGHT GAIN;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MIGRAINE DISORDERS;

EID: 15944379277     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.2.145     Document Type: Editorial

References (32)

1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 44(Suppl. 4), S24-S39 (1994).
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45-68 (1995).
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1-160 (1994).
4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231-238 (1996).
5. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1-13 (1997).
6. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Willians & Wilkins, PA, USA, 385-389 (2000).
7. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff's Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 121-246 (2001).
8. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611-634 (2002).
9. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23, 961-962 (2003).
10. Krymchantowski AV, Hampshire F. Porytherapy in migraine prevention. Clinical experience with the combination of a β-blocker plus a tricyclic antidepressant plus a calcium channel blocker. Headache 44, 499-500 (2004).
11. Shachter SC. Epilepsy. Neurol. Clin. 19, 57-78 (2001).
12. Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr. Pain Headache Rep. 8(3), 244-250 (2004).
13. Krymchantowski AV, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Med. Gen. Med. 6(3), 48 (2004).
14. Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36-52 (2001).
15. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
16. Lipton RB, Stewart WF, Cady R et al. 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40, 783-791 (2000).
17. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3-9 (2002).
18. 1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 411-438 (2000).
19. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18-22 (1998).
20. Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 44, 1587-1592 (1994).
21. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 36, 471-475 (1996).
22. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21-28 (1995).
23. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51 (1996).
24. Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol. 28(4), 1-4 (2004).
25. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2-3), 107-110 (2001).
26. Lance JW. Headache. Ann. Neurol. 10, 1-10 (1981).
27. Wilkinson M. treatment of the acute migraine attack - current status. Cephalalgia 3, 61-67 (1983).
28. Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 26, 168-171 (1986).
29. Krymchantowski AV, Adriano M, Fernandes O. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 19, 186-187 (1999).
30. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsiquiatr. 58(2-B), 428-430 (2000).
31. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309-312 (2002).
32. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 4(1), 10 (2004).